Transcriptional regulation of bone and joint remodeling by NFAT

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 286-300

  Sitara, Despina ^a   Aliprantis, Antonios O ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

NFAT; Osteoarthritis; Osteoblast; Osteoclast; Osteoporosis; Rheumatoid arthritis

Indexed keywords

BOMBESIN; CALCINEURIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SUBSTANCE P; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANGIOGENESIS; BONE REMODELING; CARTILAGE CELL; ENDOTHELIUM CELL; FIBROUS DYSPLASIA; GENE EXPRESSION REGULATION; HUMAN; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; NOCICEPTION; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE REMODELING; CALCINEURIN; CHONDROGENESIS; HUMANS; JOINTS; NEOVASCULARIZATION, PATHOLOGIC; NFATC TRANSCRIPTION FACTORS; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PAIN; TRANSCRIPTION, GENETIC;

EID: 73249128394     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00849.x     Document Type: Review

References (147)

1. Harris ED Jr. The bone and joint decade: a catalyst for progress. Arthritis Rheum 2001 44 : 1969 1970.
2. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003 81 : 646 656.
3. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002 2 : 389 406.
4. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007 9 (Suppl S1.
5. Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging 2006 23 : 773 779. (Pubitemid 44664668)
6. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 2006 20 : 2492 2506.
7. Simkin PA, Gardner GC. The musculoskeletal system and joint physiology. In : Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Rheumatology. 4th edn. Philadelphia : Elsevier, 2008 : 33 43.
8. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008 223 : 252 270.
9. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006 20 : 1003 1025.
10. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007 213 : 626 634.
11. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005 208 : 228 251.
12. Shaw J, Utz P, Durand D, Toole J, Emmel E, Crabtree G. Identification of a putative regulator of early T cell activation genes. Science 1988 241 : 202 205.
13. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003 17 : 2205 2232.
14. Graef IA, Gastier JM, Francke U, Crabtree GR. Evolutionary relationships among Rel domains indicate functional diversification by recombination. Proc Natl Acad Sci USA 2001 98 : 5740 5745.
15. Im SH, Rao A. Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. Mol Cells 2004 18 : 1 9.
16. Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. Curr Opin Genet Dev 2001 11 : 505 512.
17. Wu H, Peisley A, Graef IA, Crabtree GR. NFAT signaling and the invention of vertebrates. Trends Cell Biol 2007 17 : 251 260.
18. Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 2008 132 : 299 310.
19. Aliprantis AO, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008 118 : 3775 3789.
20. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 423 : 356 361.
21. Services UDoHaH. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD : US Department of Health and Human Services, Office of the Surgeon General, 2004.
22. Carlsten H. Immune responses and bone loss: the estrogen connection. Immunol Rev 2005 208 : 194 206.
23. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004 34 : 593 598.
24. Lian JB, et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004 14 : 1 41.
25. Nakashima K, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002 108 : 17 29.
26. Otto F, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997 89 : 765 771.
27. Balcerzak M, et al. The roles of annexins and alkaline phosphatase in mineralization process. Acta Biochim Pol 2003 50 : 1019 1038.
28. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003 423 : 337 342.
29. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003 4 : 638 649.
30. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004 351 : 2839 2849.
31. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005 208 : 30 49.
32. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006 12 : 17 25.
33. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 : 315 323.
34. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998 188 : 997 1001.
35. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005 208 : 181 193.
36. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005 208 : 126 140.
37. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells 2004 17 : 1 9.
38. Jimi E, Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 2005 208 : 80 87.
39. Lorenzo J, Choi Y. Osteoimmunology. Immunol Rev 2005 208 : 5 6.
40. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005 208 : 19 29.
41. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 : 309 319.
42. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008 19 : 444 451.
43. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 2002 65 : 44 48.
44. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004 36 : 372 378.
45. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002 61 (Suppl ii84 ii86.
46. Pettit AR, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001 159 : 1689 1699.
47. Gravallese EM, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000 43 : 250 258.
48. Diarra D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007 13 : 156 163.
49. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2007 19 : 238 245.
50. Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med 2006 354 : 841 848.
51. Pessler F, Dai L, Cron RQ, Schumacher HR. NFAT transcription factors - new players in the pathogenesis of inflammatory arthropathies? Autoimmun Rev 2006 5 : 106 110.
52. Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008 10 (Suppl S5.
53. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005 5 : 472 484.
54. Yoo SA, et al. Calcineurin is expressed and plays a critical role in inflammatory arthritis. J Immunol 2006 177 : 2681 2690.
55. Cho ML, et al. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. Arthritis Rheum 2002 46 : 42 51.
56. Masuda K, et al. Molecular profile of synovial fibroblasts in rheumatoid arthritis depends on the stage of proliferation. Arthritis Res 2002 4 : R8.
57. Gerth AJ, Pham CT, Peng SL. Regulation of the symmetry and intensity of immune complex-mediated synovitis by nuclear factor of activated T cells. Arthritis Rheum 2004 50 : 3392 3395.
58. Ji H, et al. Arthritis critically dependent on innate immune system players. Immunity 2002 16 : 157 168.
59. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002 297 : 1689 1692.
60. Kim ND, Chou RC, Seung E, Tager AM, Luster AD. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006 203 : 829 835.
61. Chen M, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006 203 : 837 842.
62. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002 3 : 889 901.
63. Takayanagi H. The role of NFAT in osteoclast formation. Ann NY Acad Sci 2007 1116 : 227 237.
64. Shinohara M, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008 132 : 794 806.
65. Asagiri M, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005 202 : 1261 1269.
66. Ishida N, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002 277 : 41147 41156.
67. Sun L, et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol 2007 292 : F285 F291.
68. Day CJ, et al. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J Cell Biochem 2004 91 : 303 315.
69. Kuroda Y, Hisatsune C, Nakamura T, Matsuo K, Mikoshiba K. Osteoblasts induce Ca2 + oscillation-independent NFATc1 activation during osteoclastogenesis. Proc Natl Acad Sci USA 2008 105 : 8643 8648.
70. Ranger AM, et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998 392 : 186 190.
71. Winslow MM, et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 2006 10 : 771 782.
72. Ueki Y, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007 128 : 71 83.
73. Ueki Y, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001 28 : 125 126.
74. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005 208 : 154 168.
75. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007 40 : 251 264.
76. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 2001 14 : 13 20.
77. Kaminuma O, et al. Differential contribution of NFATc2 and NFATc1 to TNF-alpha gene expression in T cells. J Immunol 2008 180 : 319 326.
78. Lietman SA, Yin L, Levine MA. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008 371 : 644 648.
79. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006 372 : 92 102.
80. Kim K, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005 280 : 35209 35216.
81. Sharma SM, et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 2007 282 : 15921 15929.
82. Shen Z, Crotti TN, Flannery MR, Matsuzaki K, Goldring SR, McHugh KP. A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta 2007 1769 : 659 667.
83. Mizuno A, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998 247 : 610 615.
84. Glass DA 2nd., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005 8 : 751 764.
85. Rousselle AV, Heymann D. Osteoclastic acidification pathways during bone resorption. Bone 2002 30 : 533 540.
86. Wu J, Glimcher LH, Aliprantis AO. HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci USA 2008 105 : 16934 16939.
87. Alper SL. Molecular physiology of SLC4 anion exchangers. Exp Physiol 2006 91 : 153 161.
88. Wang Z, Schultheis PJ, Shull GE. Three N-terminal variants of the AE2 Cl-/HCO3- exchanger are encoded by mRNAs transcribed from alternative promoters. J Biol Chem 1996 271 : 7835 7843.
89. Gawenis LR, et al. Mice with a targeted disruption of the AE2 Cl-/HCO3- exchanger are achlorhydric. J Biol Chem 2004 279 : 30531 30539.
90. Josephsen K, et al. Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice. Proc Natl Acad Sci USA 2009 106 : 1638 1641.
91. Sun L, et al. Calcineurin regulates bone formation by the osteoblast. Proc Natl Acad Sci USA 2005 102 : 17130 17135.
92. Yeo H, et al. Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J Biol Chem 2007 282 : 35318 35327.
93. Yeo H, Beck LH, McDonald JM, Zayzafoon M. Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone 2007 40 : 1502 1516.
94. Koga T, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005 11 : 880 885.
95. Choo MK, Yeo H, Zayzafoon M. NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation. Bone 2009 45 : 579 589.
96. Schroeder TM, Nair AK, Staggs R, Lamblin AF, Westendorf JJ. Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics 2007 8 : 362.
97. Penolazzi L, et al. Induction of estrogen receptor alpha expression with decoy oligonucleotide targeted to NFATc1 binding sites in osteoblasts. Mol Pharmacol 2007 71 : 1457 1462.
98. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005 328 : 688 696.
99. Ranger AM, et al. The transcription factor NFATp is a repressor of chondrogenesis. J Exp Med 2000 191 : 9 21.
100. Nishigaki F, Sakuma S, Ogawa T, Miyata S, Ohkubo T, Goto T. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol 2002 437 : 123 128.
101. Wang J, et al. Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. J Pathol 2009 219 : 163 172.
102. Thirunavukkarasu K, et al. Regulation of the human ADAMTS-4 promoter by transcription factors and cytokines. Biochem Biophys Res Commun 2006 345 : 197 204.
103. Yaykasli KO, et al. ADAMTS9 activation by interleukin 1 beta via NFATc1 in OUMS-27 chondrosarcoma cells and in human chondrocytes. Mol Cell Biochem 2009 323 : 69 79.
104. Yoo SA, et al. Calcineurin modulates the catabolic and anabolic activity of chondrocytes and participates in the progression of experimental osteoarthritis. Arthritis Rheum 2007 56 : 2299 2311.
105. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998 41 : 951 962.
106. Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008 2008 : 129873.
107. Nilsson LM, Nilsson-Ohman J, Zetterqvist AV, Gomez MF. Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? Curr Opin Lipidol 2008 19 : 483 490.
108. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001 105 : 863 875.
109. Ribatti D, et al. An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis. Inflamm Res 2000 49 : 418 423.
110. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006 21 : 557 566.
111. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006 12 : 5018 5022.
112. Koch AE, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994 152 : 4149 4156.
113. Lee SS, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001 19 : 321 324.
114. Choi ST, Kim JH, Seok JY, Park YB, Lee SK. Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 2009 28 : 333 337.
115. Clavel G, et al. Relationship between angiogenesis and inflammation in experimental arthritis. Eur Cytokine Netw 2006 17 : 202 210.
116. Hernandez GL, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001 193 : 607 620.
117. Jinnin M, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008 14 : 1236 1246.
118. Yoo SA, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 2009 60 : 345 354.
119. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000 191 : 426 433.
120. Luttun A, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002 8 : 831 840.
121. Cho ML, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002 46 : 1202 1209.
122. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford) 1999 38 : 714 720.
123. Sharaki OA, El-Guiziry DA, Abou-Zeid AA, El-Noueam KI, Helal AE, Gaballah AE. Clinical usefulness of basic fibroblast growth factor and E-selectin in patients with rheumatoid arthritis. Egypt J Immunol 2004 11 : 91 100.
124. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004 199 : 1513 1522.
125. Courtwright A, et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res 2009 69 : 4621 4628.
126. Niissalo S, Hukkanen M, Imai S, Tornwall J, Konttinen YT. Neuropeptides in experimental and degenerative arthritis. Ann NY Acad Sci 2002 966 : 384 399.
127. Green PG. Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. Arthritis Res Ther 2005 7 : 111 113.
128. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987 235 : 893 895.
129. Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005 7 : R416 R426.
130. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001 7 : 563 568.
131. Ganea D, Gonzalez-Rey E, Delgado M. A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. J Neuroimmune Pharmacol 2006 1 : 400 409.
132. Quinlan KL, et al. Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 1999 163 : 5656 5665.
133. Seybold VS, Coicou LG, Groth RD, Mermelstein PG. Substance P initiates NFAT-dependent gene expression in spinal neurons. J Neurochem 2006 97 : 397 407.
134. Corral RS, Iniguez MA, Duque J, Lopez-Perez R, Fresno M. Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. Oncogene 2007 26 : 958 969.
135. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. J Immunol 2001 166 : 1028 1040.
136. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002 47 : 391 397.
137. Ranzolin A, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009 61 : 794 800.
138. Jackson JG, Usachev YM, Thayer SA. Bradykinin-induced nuclear factor of activated T-cells-dependent transcription in rat dorsal root ganglion neurons. Mol Pharmacol 2007 72 : 303 310.
139. Barthel C, et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther 2009 11 : R82.
140. Groth RD, Coicou LG, Mermelstein PG, Seybold VS. Neurotrophin activation of NFAT-dependent transcription contributes to the regulation of pro-nociceptive genes. J Neurochem 2007 102 : 1162 1174.
141. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 1993 16 : 99 104.
142. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009 7 : 18 22.
143. Cohen SB, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008 58 : 1299 1309.
144. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005 280 : 32905 32913.
145. Crotti TN, et al. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol 2008 215 : 636 644.
146. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 2008 22 : 176 185.
147. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007 313 : 168 178.